Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer
Therapeutic Advances in Medical Oncology
Published online on June 17, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:While trifluridine/tipiracil (FTD/TPI) is approved for refractory metastatic colorectal cancer (mCRC), its clinical benefit may vary based on molecular and clinical characteristics.Objectives:To identify clinical and molecular factors ...
Background:While trifluridine/tipiracil (FTD/TPI) is approved for refractory metastatic colorectal cancer (mCRC), its clinical benefit may vary based on molecular and clinical characteristics.Objectives:To identify clinical and molecular factors ...